Literature DB >> 14624344

[Complementary and alternative medicine in urologic oncology].

T Otto1, J Suhr, H Rübben.   

Abstract

The great majority of phytotherapeutic, homeopathic and anthroposophical medicines are subject to the regulations in their respective field of application, implying a simple licensing process. In contrast with conventional medications in the area of oncology, some unconventional agents are given in observation studies without the prior testing of quality, side effects and efficacy that is normal in oncology. Unconventional therapeutics cannot be considered equivalent to placebo preparations. Since they may have an immunomodulatory action, one cannot exclude possible long-term adverse effects, including progression of tumors. To date there is no clear indication for routine use of unconventional therapeutic agents in urological oncology. A scientific evaluation according to the criteria of evidence-based medicine is required. This article presents proven results of treatment with unconventional medicines in urooncology against the background of the respective spectrum of methods.

Entities:  

Mesh:

Year:  2003        PMID: 14624344     DOI: 10.1007/s00120-003-0458-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

1.  Vaginal erosion after pubovaginal sling procedures using dermal allografts.

Authors:  Catherine S Bradley; Mark A Morgan; Lily A Arya; Eric S Rovner
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

2.  Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.

Authors:  G. Lümmen; S. Blass-Kampmann; H. Rübben; J. Suhr; T. Otto
Journal:  Onkologie       Date:  2000-10

3.  Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

Authors:  R A Figlin; W C Pierce; R Kaboo; C L Tso; N Moldawer; B Gitlitz; J deKernion; A Belldegrun
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

Review 4.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

5.  Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe.

Authors:  D Lenartz; U Dott; J Menzel; J M Schierholz; J Beuth
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

6.  Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study.

Authors:  T Otto; A Bex; S Krege; P H Walz; H Rübben
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

7.  Intravesical therapy with pertussis toxin before radical cystectomy in patients with bladder cancer: a Phase I study.

Authors:  T Otto; G Lümmen; T Kälble; F Recker; S Krege; A Bex; F Noll; H Rübben
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

Review 8.  Chemoprevention strategies for prostate cancer.

Authors:  Maarten C Bosland; David L McCormick; Jonathan Melamed; Paul D Walden; Anne Zeleniuch-Jacquotte; L H Lumey
Journal:  Eur J Cancer Prev       Date:  2002-08       Impact factor: 2.497

9.  The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial.

Authors:  M K Steuer-Vogt; V Bonkowsky; P Ambrosch; M Scholz; A Neiss; J Strutz; M Hennig; T Lenarz; W Arnold
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

10.  Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population.

Authors:  Lars Henningsohn; Kenneth Steven; Else Brohm Kallestrup; Gunnar Steineck
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.